Marketwire - AFEXA LIFE SCIENCES INC. - 2011

Afexa Announces Results of the Special Meeting and Privatization of Afexa

Mon, 12 Dec 2011 14:30:00 EST

EDMONTON, ALBERTA--(Marketwire - Dec. 12, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) announced today that at its special meeting of shareholders held earlier today in Calgary, Alberta, the shareholders approved the amalgamation of Afexa and 1625907 Alberta Ltd. (the "Offeror"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant"), and that the amalgamation was subsequently completed. The amalgamation constitutes the subsequent acquisition transaction following the offer from the Offeror to acquire all the issued and outstanding common shares of Afexa ("Common Shares") and results in the privatization of Afexa.

Afexa Mails Information Circular in Connection with its Privatization

Wed, 16 Nov 2011 17:00:00 EST

EDMONTON, ALBERTA--(Marketwire - Nov. 16, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) announced today that it has mailed to its shareholders the notice of special meeting and management information circular in connection with the special shareholder meeting to approve the amalgamation of Afexa and 1625907 Alberta Ltd. (the "Offeror"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant").

Afexa Announces Results for Fiscal 2012 Second Quarter

Fri, 11 Nov 2011 17:28:00 EST

EDMONTON, ALBERTA--(Marketwire - Nov. 11, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) today announced that during the quarter ended September 30, 2011 revenue of $15.0 million was achieved, reflecting a 21.9% decrease over the same three-month period in 2010.�For the six-month period ended September 30, 2011 revenue of $19.6 million was achieved which is $1.4 million or 6.6% lower than the $21.0 million achieved in the same period ending September 30, 2010.�The reduced revenue is primarily due to a reduction of orders from one significant customer and the prevalence of relatively low incidences of flu at the beginning of this year's cold and flu season.�

Afexa Announces Additional Take-Up of Shares Under Valeant Offer and Special Meeting of Shareholders to Approve the Privatization of Afexa

Thu, 27 Oct 2011 23:43:00 EDT

EDMONTON, ALBERTA--(Marketwire - Oct. 27, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announced today that it has been advised by 1625907 Alberta Ltd. (the "Offeror"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant"), that an additional 8,523,517 common shares ("Common Shares") of Afexa were deposited to the Offeror's offer (the "Valeant Offer") to acquire all of the issued and outstanding Common Shares and that all such Common Shares have been taken up and will be paid for in accordance with the terms of the Valeant Offer.�Together with the Common Shares previously taken up on October�17, 2011, the Common Shares taken up under the Valeant Offer represent approximately 81.6% of the issued and outstanding Common Shares (on a fully-diluted basis).�Afexa's shareholders

Afexa Announces Appointment of New Chair and President and CEO

Tue, 18 Oct 2011 20:19:00 EDT

EDMONTON, ALBERTA--(Marketwire - Oct. 18, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announced today that Robert Chai-Onn, Executive Vice President, General Counsel and Corporate Secretary of Valeant Pharmaceutical International, Inc. has been appointed the Chairman of the Board of Directors of the Company.�Thomas Schlader, President of Valeant Canada Limited has been appointed the President and Chief Executive Officer of the Company.

Afexa Announces Take-Up of Shares Under Valeant Offer

Tue, 18 Oct 2011 01:24:00 EDT

EDMONTON, ALBERTA--(Marketwire - Oct. 18, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announced today that it has been advised by 1625907 Alberta Ltd. (the "Offeror"), a wholly-owned subsidiary of Valeant Pharmaceuticals, Inc. ("Valeant"), that 80,929,921 common shares ("Common Shares") of Afexa were deposited to the Offeror's offer (the "Valeant Offer") dated October 3, 2011 to acquire all of the issued and outstanding Common Shares and that all such Common Shares have been taken up and will be paid for in accordance with the terms of the Valeant Offer.�The Common Shares taken up under the Valeant Offer represent approximately 73.8% of the issued and outstanding Common Shares (on a fully-diluted basis).�Afexa's shareholders who tendered to the Valeant Offer will receive C$0.85 per share in cash which will be paid to Afexa's shareholders in accorda

Afexa Files Notice of Change to Directors' Circulars

Tue, 04 Oct 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Oct. 4, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announced today that it has filed a notice of change (the "Notice of Change") to its prior directors' circulars on SEDAR (available at www.sedar.com and on the Company's website www.afexa.com) in connection with:

Afexa Provides Recommendation That Shareholders Accept the Increased Valeant Offer

Fri, 30 Sep 2011 17:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Sept. 30, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announced today that�it has entered into an agreement (the "Agreement") with Valeant Pharmaceuticals International, Inc. ("Valeant") and 1625907 Alberta Ltd. (the "Offeror"), a wholly-owned subsidiary of Valeant, pursuant to which the Offeror has agreed to amend its offer dated September 6, 2011 to purchase all of the issued and outstanding common shares (the "Common Shares") of Afexa.�Pursuant to the amendment, holders of Common Shares will receive $0.85 in cash per share (the "Increased Valeant Offer").�Valeant had previously announced by news release dated September 26, 2011 its intention, subject to certain conditions, to make the Increased Valeant Offer.

Afexa Provides Update on Takeover Offers and ASC Decision on Shareholder Rights Plans

Wed, 28 Sep 2011 18:28:00 EDT

EDMONTON, ALBERTA--(Marketwire - Sept. 28, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announced today that Paladin Labs Inc. ("Paladin") has amended its offer for any and all of the common shares of Afexa (the "Amended Paladin Offer") by way of a Notice of Variation and Extension dated September�26, 2011.�Under the Amended Paladin Offer, holders of common shares can elect either $0.81 per share in cash or 0.0217 of a Paladin share for each common share of Afexa.�The Amended Paladin Offer is subject to the same conditions as the original offer by Paladin mailed to Afexa shareholders on August�10, 2011, except that it is also a condition of the Amended Paladin Offer that no increase shall have been made to the "Termination Fee" as defined in the acquisition support agreement (the "Support Agreement") dated August�30,

Afexa Comments on Paladin's Announced Intention to Enhance Its Takeover Offer for Afexa

Thu, 22 Sep 2011 15:57:00 EDT

EDMONTON, ALBERTA--(Marketwire - Sept. 22, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - responded to a news release issued today by Paladin Labs Inc. ("Paladin")�announcing Paladin's intention to enhance its unsolicited takeover offer ("Offer") for all and any of the outstanding shares of Afexa Life Sciences Inc.�in the event that Afexa's two shareholder rights plans (dated January�25, 2010 and August 12, 2011) are waived by Afexa or cease-traded by the ASC within a reasonable time of a hearing to be held by the Alberta Securities Commission to consider an application made by Paladin to cease trade the rights plans. The hearing is scheduled for September 23, 2011.

Afexa Mails Circular in Support of Valeant Offer and Appoints Interim CEO for Transition

Fri, 09 Sep 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Sept. 9, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - today announced that its Board of Directors (the "Board") confirmed its previous recommendation that Afexa shareholders (the "Shareholders") accept the offer by 1625907 Alberta Ltd. ("Acquireco"), a subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant"), pursuant to which Acquireco has agreed to acquire all of the outstanding common shares of Afexa for $0.71 per share in cash (the "Valeant Offer").

In Schools, Homes and the Workplace, the Cost of Colds in Canada is "Enormous" According to A Report Released Today by Queen's University Researchers

Tue, 06 Sep 2011 08:00:00 EDT

They Say More Emphasis Should Be Put on Prevention.

COLDSORE-FX(R) Launched to Treat 7 Million Canadians Who Suffer Troubling Infection With Social Stigma

Wed, 31 Aug 2011 08:00:00 EDT

TORONTO, ONTARIO--(Marketwire - Aug. 31, 2011) -

Afexa Agrees to Support an Offer by Valeant Pharmaceuticals

Tue, 30 Aug 2011 09:28:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 30, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA)- the maker of COLD-FX^�- today announced that it has entered into a definitive acquisition support agreement (the "Agreement") with 1625907 Alberta Ltd. ("Acquireco"), a subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant") pursuant to which Acquireco has agreed to acquire all of the outstanding common shares of Afexa for $0.71 per share in cash (the "Valeant Offer"). The Valeant Offer represents a premium of approximately 30% to the 30-trading day volume weighted average closing price on the Toronto Stock Exchange, a 49% premium over the closing price the day before the hostile bid (the "Paladin Bid") from Paladin Labs Inc. ("Paladin") and a 29% premium to the $0.55 cash consideration under the Paladin Bid or a 49% premium to the share consideration alternative of 0.013 of a Paladin

Afexa Announces Completion of Interim Analysis on COLD-FX Pediatric Multi-Centre Clinical Trial: Encouraging Trend Observed

Fri, 26 Aug 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 26, 2011) - Afexa Life Sciences Inc. (TSX:FXA) today announced the encouraging results of an interim analysis performed by an independent data monitoring committee (IDMC) for the currently in-progress COLD-FX� clinical trial in a pediatric population.�The IDMC has completed a review of the data obtained to date and unanimously recommended that the study continue into the 2011/2012 cold and flu season.�

Afexa's Board Unanimously Confirms Previous Recommendation That Shareholders Reject Paladin's Unsolicited Offer

Tue, 23 Aug 2011 23:03:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 23, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - today announced that its Board of Directors (the "Board") unanimously confirmed its previous recommendation that Afexa shareholders (the "Shareholders") reject the unsolicited offer by Paladin Labs Inc. to acquire all of the outstanding shares of Afexa (the "Common Shares") for either cash consideration of Cdn$0.55 per common share or 0.013 of a Paladin share for each common share (the "Paladin Offer").

Afexa Announces Results for Fiscal 2012 First Quarter

Fri, 19 Aug 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 19, 2011) -

Afexa Announces Results of a Clinical Trial of Dilexaponan(TM) for Cholesterol Management

Thu, 18 Aug 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 18, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - today announced promising results of a pilot clinical study investigating the effects of a new formulation, DilexaponanT (LIP-01) on cholesterol management.�Dilexaponan is a proprietary polymolecular formulation isolated from botanical sources and developed and standardized using ChemBioPrint technology.

TSX Defers Consideration of Afexa Shareholder Rights Plan

Wed, 17 Aug 2011 17:21:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 17, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - announces that it has been notified by the Toronto Stock Exchange (the "TSX") that the TSX will defer consideration of the acceptance of Afexa's new shareholder rights plan (the "Rights Plan") until such time as the TSX is satisfied that the appropriate securities commission will not intervene pursuant to National Policy 62-202 - Take-Over Bids - Defensive Tactics.�Pursuant to TSX policies, the TSX automatically defers acceptance of shareholder rights plans adopted in response to a specific take-over bid.

Afexa Adopts New Shareholder Rights Plan and Extends Separation Time Under Shareholder Rights Plans

Sun, 14 Aug 2011 21:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 14, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - has adopted a new shareholder rights plan (the "New Rights Plan").�The New Rights Plan has been adopted to limit, to the extent possible, the ability of any investor to obtain effective control of Afexa through coercive and opportunistic methods without making a take-over bid offer to all shareholders of Afexa which a majority of shareholders find acceptable and otherwise to encourage fair treatment of shareholders in connection with any take-over bid offer for Afexa's common shares.�The Board of Directors did not adopt the New Rights Plan to prevent a takeover of the Company, to secure the continuance of management or the directors in their respective offices or to deter fair offers for the common shares of the Company.�

Afexa AGM Highlights Short and Long-Term Growth

Wed, 10 Aug 2011 12:41:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 10, 2011) - Afexa Life Sciences Inc. ("Afexa" or "the Company") (TSX:FXA) outlined today at their shareholders Annual General Meeting ("AGM") the progress the Company is making towards growing its integrated business given its component parts; Serial product development, the Globalization of COLD-FX^�, and the Canadian Commercial Business.

Afexa Responds to Unsolicited Bid

Wed, 10 Aug 2011 10:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - Aug. 10, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX(R) - was today advised that Paladin Labs Inc. ("Paladin") has filed documents with Canadian securities authorities formally commencing an unsolicited tender offer to acquire all of the outstanding common shares of the Company for either cash consideration of Cdn $0.55 per common share or 0.013 of a Paladin share for each common share ("the Offer").

Afexa Comments on Recent Shareholder Announcement

Mon, 18 Jul 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - July 18, 2011) - Afexa Life Sciences Inc. (TSX:FXA)

Afexa Announces U.S. FDA IND Clearance for Clinical Trial of AFX-2 in Patients With Chronic Lymphocytic Leukemia

Mon, 18 Jul 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - July 18, 2011) - Afexa Life Sciences Inc. (TSX:FXA) today announced the U.S. Food and Drug Administration (FDA) authorization of a Phase 1B clinical trial of AFX-2 (CVT-E002T) as an Investigational New Drug (IND) in adults with Chronic Lymphocytic Leukemia (CLL).

Paula Findlay joins the IMMUNITY-FX� team as brand ambassador for healthy, active lifestyles

Fri, 08 Jul 2011 23:59:00 EDT

EDMONTON, ALBERTA--(Marketwire - July 8, 2011) - Afexa Life Sciences is proud to announce the designation of record-holding World Champion Series Canadian triathlete Paula Findlay as ambassador for its product IMMUNITY-FX. As an Official Supplier to Canada's Olympic athletes, and Certified for SportT by NSF International, IMMUNITY-FX is a daily immune system supplement that is a natural solution to today's busy lifestyles. "

Afexa Announces CEO Succession Process

Fri, 24 Jun 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - June 24, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX^� - today announced that the Human Resources and Compensation Committee of the Board is leading the process to assist the Board in identifying its new Chief Executive Officer to replace Mr.�Jack�Moffatt when his contract expires at the end of September, 2011.�Thereafter, Mr. Moffatt will continue to be available to assist the Company as needed under a revised employment contract for a period of one year.

Best Buy Canada Ltd. CFO Joins Afexa Board

Thu, 23 Jun 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - June 23, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA), maker of COLD-FX^�, announced the appointment of Annalisa�King, Senior Vice President and CFO of Best Buy Canada Ltd., to its Board of Directors. Ms. King brings the board complement to eight.�

Afexa Announces 2011 Annual Financial Results

Fri, 10 Jun 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - June 10, 2011) - Afexa Life Sciences Inc. ("Afexa" or "the Company") (TSX:FXA) today announced its financial results for the year ended March 31, 2011.�

Afexa Announces Results of Clinical Trial With Chronic Lymphocytic Leukemia Patients

Thu, 02 Jun 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - June 2, 2011) - Afexa Life Sciences Inc. (TSX:FXA) - the maker of COLD-FX^� - today announced results of a clinical trial exploring the potential application of CVT-E002T, in chronic lymphocytic leukemia (CLL). The immune system, particularly antibody responses, in CLL patients is compromised and, as in all cases of immune suppression, infection is common in this population. This is the first time CVT-E002 has been studied in a cancer clinical trial exploring the role of CVT-E002 in reducing the incidence and severity of acute respiratory infections for CLL patients.�

Afexa Appoints William White as Independent Chairman

Thu, 31 Mar 2011 08:00:00 EDT

EDMONTON, ALBERTA--(Marketwire - March 31, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) today announced the appointment of William B. White as Independent Chairman of the Board of Directors of Afexa, effective April 1, 2011.

COLD-FX Partners With Canadian Cycling to Promote Active and Healthy Living

Wed, 30 Mar 2011 20:56:00 EDT

Growth of cycling and the success of the Canadian Cycling Team becoming an attractive property for corporate Canada

Afexa Announces 2011 Third Quarter Results

Fri, 11 Feb 2011 08:00:00 EST

- Lower incidence of colds and flu during the quarter

- Net earnings $0.9 million or $0.01 per share

- Balance sheet remains strong with $9.1 million cash position

Afexa Life Sciences Inc., Maker of COLD-FX(R), Appoints Tracey Ramsay as Chief Marketing Officer and Senior Vice President Sales

Fri, 21 Jan 2011 12:15:00 EST

EDMONTON, ALBERTA--(Marketwire - Jan. 21, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA), maker of COLD-FX, announced that Ms. Tracey Ramsay has agreed to join the Company, effective January 31, 2011 as Chief Marketing Officer and Senior Vice President Sales. Ms. Ramsay will serve on Afexa's Executive Leadership Team, and will report directly to the Chairman and Chief Executive Officer.

Afexa Life Sciences Sets the Record Straight

Wed, 19 Jan 2011 08:00:00 EST

EDMONTON, ALBERTA--(Marketwire - Jan. 19, 2011) - Afexa Life Sciences Inc. ("Afexa") (TSX:FXA) wishes to set the record straight.�After a thorough review of our contractual arrangements and other dealings with Alberta Health Services ("AHS") in relation to our multi-centre pediatric clinical trial involving COLD-FX^�, we feel clarifying the public record is required, given the recent media interest in this trial.